ORIC Pharmaceuticals Inc.

**Signal Note: EcoR1 Capital Entry into ORIC** EcoR1's $55M initiation suggests conviction in ORIC's pipeline timing, likely driven by upcoming catalysts for lead program ORIC-101 (GPRC120 agonist) in ulcerative colitis, which showed clinical benefit in Phase 2b and is advancing toward late-stage development. The crossover investor's entry at scale indicates belief in near-term value inflection from clinical readouts or partnership developments, though ORIC's commercial execution risk remains material given the crowded inflammatory bowel disease space.